Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$84.88 USD

84.88
359,409

+0.71 (0.84%)

Updated Apr 17, 2024 04:00 PM ET

After-Market: $84.99 +0.11 (0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (97 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why You Should Add Haemonetics (HAE) to Your Portfolio Now

by Zacks Equity Research

Recovery within the Hospital business and the favorable prospects of the Plasma franchise raise investors' optimism for Haemonetics (HAE).

HAE vs. ABT: Which Stock Is the Better Value Option?

by Zacks Equity Research

HAE vs. ABT: Which Stock Is the Better Value Option?

Haemonetics' (HAE) New TEG 6s Cartridge Gets FDA Approval

by Zacks Equity Research

Haemonetics' (HAE) TEG testing gives vital information that can assist doctors with better control of their patients' hemostasis.

Haemonetics (HAE) Crossed Above the 200-Day Moving Average: What That Means for Investors

by Zacks Equity Research

Should investors be excited or worried when a stock crosses above the 200-day simple moving average?

Haemonetics (HAE) Recently Broke Out Above the 50-Day Moving Average

by Zacks Equity Research

Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?

Haemonetics (HAE) Signs Agreement to Acquire Attune Medical

by Zacks Equity Research

Haemonetics' (HAE) acquisition of the privately held Attune Medical is likely to add the pioneering ensoETM device to its EP portfolio.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

What Makes Haemonetics (HAE) a New Buy Stock

by Zacks Equity Research

Haemonetics (HAE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

HAE or SYK: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HAE vs. SYK: Which Stock Is the Better Value Option?

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Haemonetics (HAE) Q3 Earnings Top Estimates, 2024 View Raised

by Zacks Equity Research

Haemonetics' (HAE) proprietary technology, Persona, continues to gain momentum in the third quarter.

Here's Why Haemonetics (HAE) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

IDEXX's (IDXX) Global Growth Continues, Currency Woes Persist

by Zacks Equity Research

A key element of IDEXX's (IDXX) customer engagement strategy is the expansion of its commercial footprint in a disciplined approach.

Zimmer Biomet (ZBH) Q4 Earnings Top Estimates, Margins Grow

by Zacks Equity Research

Each of Zimmer Biomet's (ZBH) geographic segments records strong year-over-year sales growth on a reported basis, as well as at CER in the fourth quarter.

Haemonetics (HAE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Haemonetics (HAE) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Haemonetics (HAE) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Haemonetics (HAE) delivered earnings and revenue surprises of 7.22% and 4.13%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

CVS Health (CVS) Q4 Earnings Top Estimates, 2024 EPS View Down

by Zacks Equity Research

Robust sales growth across all three operating segments contributes to CVS Health's (CVS) Q4 revenues.

Edwards Lifesciences (EW) Q4 Earnings Meet, Margins Dip

by Zacks Equity Research

Edwards Lifesciences' (EW) Q4 revenues register year-over-year growth on its strong differentiated portfolio of advanced therapies.

VAREX IMAGING (VREX) Lags Q1 Earnings Estimates

by Zacks Equity Research

VAREX IMAGING (VREX) delivered earnings and revenue surprises of -45.45% and 0.85%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

HAE vs. ABT: Which Stock Is the Better Value Option?

by Zacks Equity Research

HAE vs. ABT: Which Stock Is the Better Value Option?

Edwards Lifesciences (EW) Wins FDA Nod for the EVOQUE System

by Zacks Equity Research

Edwards Lifesciences' (EW) EVOQUE valve replacement system becomes the first transcatheter therapy to earn FDA approval for a tricuspid valve.

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Strength of the base business bodes well for Quest Diagnostics (DGX).

IDEXX (IDXX) Q4 Earnings Surpass Estimates, Margins Fall

by Zacks Equity Research

Across testing modalities, IDEXX (IDXX) achieves strong global growth in the fourth quarter.

Haemonetics (HAE) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Haemonetics (HAE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

Hologic's (HOLX) Q1 Earnings Beat Estimates, Gross Margin Down

by Zacks Equity Research

Hologic's (HOLX) Breast Health segment registered strong growth in Q1, primarily owing to higher capital equipment revenues.